Mabwell 9MW2821 Cervical Cancer Data to Be Presented at ESMO GC 2026 Conference

Key Takeaways

• Mabwell will present two clinical studies of 9MW2821, a Nectin-4 targeting ADC for cervical cancer at ESMO GC 2026
• The presentations include both oral and poster formats, indicating significant clinical progress in cervical cancer treatment
• Data will be shared at the European Society for Medical Oncology Gynaecological Cancers Annual Congress in Copenhagen on June 1, 2026

---

Mabwell (688062.SH, 2493.HK) announced today that clinical data from two studies of its investigational cervical cancer treatment 9MW2821 will be featured at the 2026 European Society for Medical Oncology Gynaecological Cancers (ESMO GC) Annual Congress in Copenhagen, Denmark on June 1.

The Shanghai-based biopharmaceutical company will present results through both an oral presentation and poster session, showcasing the latest clinical findings for 9MW2821, a novel antibody-drug conjugate (ADC) that targets Nectin-4.

Clinical Significance of 9MW2821

9MW2821 represents an innovative approach to cervical cancer treatment by targeting Nectin-4, a cell adhesion molecule that is overexpressed in various solid tumors including cervical cancer. As an ADC, the drug combines the targeting specificity of antibodies with the potent cell-killing ability of cytotoxic drugs, potentially offering improved efficacy with reduced systemic toxicity.

The dual presentation format at ESMO GC 2026 suggests robust clinical data that warrants both detailed discussion in an oral session and comprehensive display in poster format. This level of conference recognition typically indicates promising preliminary results that could advance the treatment landscape for cervical cancer patients.

Market Context and Company Profile

Mabwell positions itself as an innovation-driven biopharmaceutical company with a fully integrated industry chain, spanning from drug discovery through commercial manufacturing. The company’s focus on oncology therapeutics, particularly ADC technology, aligns with growing market demand for precision cancer treatments.

Cervical cancer remains a significant global health challenge, with limited treatment options for advanced or recurrent disease. Novel targeted therapies like 9MW2821 could potentially address unmet medical needs in this patient population.

The ESMO GC congress serves as a premier platform for presenting breakthrough research in gynecological cancers, making it an ideal venue for Mabwell to showcase its clinical progress to the international oncology community.

---

Frequently Asked Questions

What is 9MW2821 and how does it work?

9MW2821 is a novel antibody-drug conjugate (ADC) that targets Nectin-4, a protein overexpressed in cervical cancer cells. It combines targeted antibody therapy with cytotoxic drugs to potentially kill cancer cells more precisely while reducing side effects.

When will 9MW2821 be available for patients?

9MW2821 is currently in clinical trials. The timeline for potential approval and availability will depend on the results of ongoing studies and regulatory review processes, which typically take several years to complete.

How significant is presenting at ESMO GC 2026?

ESMO GC is a prestigious international conference for gynecological cancer research. Having both oral and poster presentations suggests Mabwell has generated meaningful clinical data that the scientific community considers noteworthy and worthy of detailed discussion.